###begin article-title 0
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 18 23 <span type="species:ncbi:9606">human</span>
Activation of the human PAX6 gene through the exon 1 enhancer by transcription factors SEF and Sp1
###end article-title 0
###begin p 1
###xml 95 119 95 119 <email xmlns:xlink="http://www.w3.org/1999/xlink">gsaunders@mdanderson.org</email>
To whom correspondence should be addressed. Tel: +1 713 792 2690; Fax: +1 713 791 9478; Email: gsaunders@mdanderson.org
###end p 1
###begin p 2
###xml 246 250 246 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 288 291 288 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 334 338 334 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 390 394 390 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 985 989 985 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 1048 1052 1048 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 1300 1308 1300 1308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1330 1337 1330 1337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1350 1354 1350 1354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 328 333 <span type="species:ncbi:9606">human</span>
###xml 683 688 <span type="species:ncbi:9606">human</span>
PAX6 is a transcription factor that plays a major role in ocular morphogenesis. PAX6 is expressed in the eye, central nervous system and pancreas. Two alternative promoters, P0 and P1, which are differentially regulated during development, drive PAX6 transcription. We identified a 57 bp cis-regulatory element in exon 1 of the human PAX6 gene exon 1 enhancer (EIE). EIE enhances P1-driven PAX6 expression. Three regions in E1E (E1E-1, E1E-2 and E1E-3) have sequence similarities with binding sites of transcription factors ARP-1, Isl-1 and SEF, respectively. As shown by electrophoretic mobility shift assays, E1E-3, but not E1E-1 or E1E-2, bound to proteins in nuclear extracts of human glioma cells and transcription factor SEF bound to E1E-3. As shown by transient transfection experiments, deletion or site-specific mutations in E1E-3 dramatically decreased P1 promoter activity. Mutations in E1E-2, however, did not affect function of the P1 promoter. Co-transfection of SEF and PAX6 promoter-reporter constructs showed that SEF up-regulates PAX6 gene expression through the P1 promoter. Two Sp1 sites in the E1E region were also shown to be important by transient co-transfection assays. Data from immunoprecipitation and transient transfection assays demonstrated that SEF and Sp1 interacted in vitro and may act together in vivo to regulate PAX6 expression.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 463 467 463 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 515 519 515 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 237 240 <span type="species:ncbi:9606">man</span>
###xml 245 250 <span type="species:ncbi:10090">mouse</span>
PAX6 is a transcription factor and the PAX6 gene acts as a master control gene for eye development. Its expression is limited to the eye, central nervous system and pancreas. PAX6 is highly conserved throughout the animal kingdom and in man and mouse the PAX6 protein is identical. The level of PAX6 protein is critical since mutations that reduce PAX6 levels result in eye phenotypes of variable severity. A reduction in PAX6 level is caused by mutations in the PAX6 gene and putative regultory regions controling PAX6 gene expression.
###end p 4
###begin p 5
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> PAX6</italic>
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c1">1</xref>
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c2">2</xref>
###xml 332 335 332 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 420 421 420 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c1">1</xref>
###xml 422 423 422 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c4">4</xref>
###xml 70 75 <span type="species:ncbi:10090">mouse</span>
###xml 384 389 <span type="species:ncbi:9606">human</span>
###xml 391 396 <span type="species:ncbi:10090">mouse</span>
 PAX6 transcription is controlled by two promoters, P0 and P1. In the mouse, P0-initiated transcripts predominate in the lens placode, cornea and conjuntival epithelia and in the developing pancreas (1,2). P1-initiated transcripts are expressed in lens placode, optic vesicle and central nervous system. The P0 promoter and several cis-acting elements have been well characterized in human, mouse, quail and pufferfish (1-4).
###end p 5
###begin p 6
###xml 85 89 85 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 144 148 144 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 157 160 157 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 224 228 224 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 327 328 327 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c3">3</xref>
###xml 329 330 329 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c4">4</xref>
###xml 438 441 438 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 539 543 539 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 597 598 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c5">5</xref>
###xml 599 600 599 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c7">7</xref>
###xml 1034 1035 1030 1031 <sub xmlns:xlink="http://www.w3.org/1999/xlink">m</sub>
###xml 1039 1040 1035 1036 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n</sub>
###xml 1147 1148 1143 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c8">8</xref>
###xml 1149 1150 1145 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c9">9</xref>
###xml 1157 1158 1153 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f1">1</xref>
###xml 1272 1276 1268 1272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 1321 1323 1317 1319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c10">10</xref>
###xml 1341 1344 1337 1340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 1383 1387 1379 1383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 1455 1459 1451 1455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 1491 1493 1487 1489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c10">10</xref>
###xml 1623 1627 1619 1623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 1818 1822 1814 1818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 369 374 <span type="species:ncbi:9606">human</span>
###xml 1377 1382 <span type="species:ncbi:9606">human</span>
###xml 1617 1622 <span type="species:ncbi:9606">human</span>
 Since little is known about the molecular mechanisms that control expression of the PAX6 gene, it is important to understand the regulation of PAX6 through cis-regulatory elements (enhancers or silencers). It is known that PAX6, as a tissue-specific regulatory gene, is transcribed from two alternative promoters (P0 and P1) (3,4) that are differentially regulated in human brain development and in adult brain plasticity. Some distinct cis elements are involved in regulating the P0 and P1 promoters and in tissue-specific expression of PAX6 in the eye, the central nervous system and pancreas (5-7) and several potential binding sites for transcription factors lie within the P0 and P1 promoters. The P0 promoter contains a TATA-like box, a CCAAT box, multiple consensus transcription factor binding sites for AP1, AP2, Sp1, c-Myb and Pit-1 and sites for the p53 transcriptional activator, NFkappaB and C/EBP protein. The P1 promoter contains a TATA-like box, two CCAAT boxes, a 38 bp polymorphic dinucleotide repeat sequence, (AC)m(AG)n, and potential transcription factor binding sites for AP1, AP2, AP4, Sp1, c-Myb, Pit-1, ARP-1, and Isl-1 (8-9; Fig. 1). Another region between -3.1 and -2.9 kb upstream of the P1 promoter contains a regulatory element that directs PAX6 expression in the developing photoreceptor (10). Other putative cis-regulatory elements involved in human PAX6 expression have been proposed to lie upstream or downstream of the PAX6 transcription initiation site (10). In this paper we report our search for such elements and our identification of a novel enhancer element in exon 1 of the human PAX6 gene, the exon 1 enhancer (EIE), which is activated by transcription factors SAA3 enhancer factor (SEF) and Sp1. We also demonstrate a physical association between SEF and Sp1 in regulating PAX6 gene expression.
###end p 6
###begin title 7
MATERIALS AND METHODS
###end title 7
###begin title 8
Cell culture
###end title 8
###begin p 9
###xml 116 119 116 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c11">11</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 258 262 <span type="species:ncbi:9913">calf</span>
###xml 335 339 <span type="species:ncbi:10090">mice</span>
Human glioma cell lines U251 and LN229 were derived from two different glioblastomas and both have mutations in the p53 gene. The cell lines were grown in a Dulbecco's modified Eagle's medium and F-12 nutrient mixture (DMEM/F-12) supplemented with 10% fetal calf serum (Gibco BRL, Rockville, MD). The degree of tumorigenicity in nu/nu mice is higher for LN229 than for U251 (11).
###end p 9
###begin title 10
Electrophoretic mobility shift assays (EMSAs)
###end title 10
###begin p 11
###xml 113 119 113 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> et al</italic>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c12">12</xref>
###xml 282 284 278 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 347 348 343 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="gke490tb1">1</xref>
EMSAs were performed using nuclear extracts of cell cultures prepared following the method described by Schreiber et al. (12). Oligomers for use in the EMSAs were synthesized to be complementary, with one dG protruding at the 5'-end of each sequence for Klenow labeling with [alpha-32P]dCTP. One strand of each oligomer sequence is shown in Table 1.
###end p 11
###begin p 12
###xml 266 267 262 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 300 302 284 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
 EMSAs were performed in a 20 microl reaction mixture that had a pH of 7.9 and contained 25 mM HEPES, 150 mM NaCl, 0.5 mM EDTA, 0.5 mM dithiothreitol (DTT), 1% Nonidet P-40, 5% glycerol, 2 mg poly(dI-dC), nuclear protein extracts containing 7-10 mg of protein and 105 c.p.m. (approximately3 fmol) of 32P-labeled oligomers. The reaction mixture was incubated at room temperature for 30 min. Samples were then loaded onto a 5% native polyacrylamide gel (19:1 crosslinking ratio). The gels were analyzed with a PhosphorImager using ImageQuant software (Molecular Dynamics, Sunnyvale, CA). For supershift assays, the binding reaction mixture was incubated with antibody or unlabeled probe at room temperature for 30 min before being loaded onto the gel.
###end p 12
###begin title 13
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
Construction of PAX6 promoter-luciferase constructs
###end title 13
###begin p 14
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 136 140 136 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c13">13</xref>
###xml 310 313 310 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sac</italic>
###xml 452 455 452 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sac</italic>
###xml 534 537 534 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sac</italic>
###xml 543 546 543 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sma</italic>
###xml 573 577 573 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
A 346 bp sequence containing the PAX6 P1 promoter and the downstream 157 bp exon 1 sequence were obtained by PCR amplification from the PAX6 promoter-CAT construct pCSMNA-b (13) using primers PAX6p-1 (5'-TGAGCTCGGGCTCGGGGGCCCTGC-3') and PAX6p-2 (5'-GGCGCCCGGCCTCGCCTCCA-3'). Primer PAX6p-1 was designed with a SacI site at the 5'-end and after blunt-end treatment with Klenow DNA polymerase (Roche, Indianapolis, IN), the PCR product was digested with SacI and cloned into a pGL3B luciferase vector (Promega, Madison, WI) between the SacI and SmaI sites in the vector. The PAX6 promoter-luciferase constructs (346pGL3B) were verified by sequencing.
###end p 14
###begin title 15
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
Construction of mutant PAX6 promoter-luciferase constructs
###end title 15
###begin p 16
###xml 253 254 253 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="gke490tb2">2</xref>
PCR-based, site-directed mutagenesis was used to create mutations in the E1E region of the 346pGL3B construct. In brief, two partially overlapping primers, designated R and F, which contained mutations, were synthesized for each mutant construct (Table 2). Using PCR, two DNA fragments were amplified from 346pGL3B plasmid DNA in two separate reactions. The first reaction (first round PCR) contained primers R and RVP3, corresponding to the vector sequence upstream of the insert, or primers F and GLP2, corresponding to the vector sequence downstream of the insert. The two PCR products of the expected sizes were isolated from the first round PCR mixtures by electrophoresis on a 2% agarose gel and were cut out, mixed together and resuspended in 400-500 microl of water by heating for 5 min at 95degreesC. An aliquot of the suspension was used in a second PCR reaction (second round PCR) with primers RVP3 and GLP2.
###end p 16
###begin p 17
###xml 613 616 529 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sac</italic>
###xml 622 625 538 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bgl</italic>
 The first round PCR conditions were 95degreesC for 1 min, 60degreesC for 1 min and 72degreesC for 1 min for one cycle, 94degreesC for 30 s, 58degreesC for 1 min and 72degreesC for 1 min for 30 cycles, and 72degreesC for 10 min for one cycle. The second round PCR conditions were 95degreesC for 1 min, 40degreesC for 1 min and 72degreesC for 1 min for one cycle, 94degreesC for 30 s, 58degreesC for 1 min and 72degreesC for 1 min for 30 cycles, and 72degreesC for 10 min for one cycle. The PCR product of the second round PCR was purified with a Gel Extraction Kit (Qiagen, Hilden, Germany). After digestion with SacI and BglII (the same sites as on the pGL3B vector), the mutated DNA fragment was removed from the 346pGL3B vector and inserted into the pGL3B vector between the corresponding digestion sites. Positive clones were selected by PCR screening with primers RVP3 and GLP2.
###end p 17
###begin p 18
###xml 114 118 114 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 177 178 177 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="gke490tb2">2</xref>
###xml 214 217 214 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sac</italic>
###xml 223 226 223 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
###xml 388 391 388 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sac</italic>
###xml 397 400 397 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
###xml 486 489 486 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sac</italic>
###xml 495 498 495 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xho</italic>
 The 346pGL3B-mSp1 construct, 346pGL3B with the Sp1 site deleted from its 3'-end, was generated by amplifying the PAX6 P1 promoter region with primers RVP3 and 3'-Sp1Xho (Table 2) and inserting the DNA between the SacI and XhoI sites of the pGL3B vector. The PCR conditions were the same as the first round PCR conditions mentioned above. The PCR product was isolated by digestion at the SacI and XhoI sites. The mutated DNA fragment was then inserted into the pGL3B vector between its SacI and XhoI sites.
###end p 18
###begin title 19
Luciferase and beta-galactosidase assays
###end title 19
###begin p 20
###xml 74 75 74 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 300 304 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
Cells were plated in 6-well tissue culture dishes at a density of 2-3 x 105 cells/well 24 h before transfection. At 60-80% confluence, cells were transfected with 0.5 microg of luciferase constructs using 3 microl FuGene6 (Roche) transfection reagent per well. Cells were co-transfected with 5 ng of SV40-pSV2 beta-galactosidase expression vector as an internal control. Forty-eight hours after transfection, cell lysates were extracted and luciferase activity was estimated using a Luciferase Assay Kit (Tropix, Bedford, MA) according to the manufacturer's protocol. Luciferase activity was measured with a luminometer (Lumat LB 9507; EG & G Berthold, Woldbad, Germany).
###end p 20
###begin p 21
###xml 172 176 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
beta-Galactosidase activity was detected using a Galacto-Light Plus chemiluminescent assay kit (Tropix) according to the manufacturer's protocol. Because SEF activates the SV40 promoter, luciferase activities were normalized to the molar amount of protein in the SEF/Sp1 co-transfection experiments.
###end p 21
###begin title 22
Immunoprecipitation and immunoblotting
###end title 22
###begin p 23
###xml 382 383 366 367 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 385 386 369 370 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 678 680 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c14">14</xref>
###xml 1265 1271 1223 1229 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> et al</italic>
###xml 1274 1276 1232 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c14">14</xref>
For co-immunoprecipitation assay of nuclear extracts approximately300-400 microg of nuclear protein from LN229 cells was diluted with binding buffer (150 mM NaCl, 12.5 mM HEPES, pH 7.9, 5 mM KCl, 0.05% Nonidet P-40, 100 mg BSA, 0.1 mM EDTA) and then supplemented with 1x Complete protease inhibitor cocktail (Roche), 1 mM DTT, 0.2 mM phenylmethylsulfonyl fluoride (PMSF) and 1 mM Na3VO4 to a total volume of 300 microl. The diluted nuclear extracts were then preabsorbed to protein G-Sepharose (Santa Cruz Biotechnology, Santa Cruz, CA) at 4degreesC for 1 h and then centrifuged at the highest speed for 3 min. The supernatant was incubated with a polyclonal anti-SEF antibody (14) at 4degreesC overnight. The immunocomplexes were then absorbed onto protein G-Sepharose at 4degreesC for 1 h and washed three times with 200 microl of phosphate-buffered saline. Elution of associated proteins in SDS sample buffer was performed by boiling for 5 min; the proteins were then resolved by 6% SDS-PAGE, transferred to a polyvinylidene difluoride (PVDF) immunoblot membrane (Qiagen), probed with anti-Sp1 antibody (Santa Cruz Biotechnology) and detected using the enhanced chemiluminescence (ECL) system (Amersham Pharmacia). The SEF antibody was prepared according to Bing et al. (14) and its specificity was demonstrated by them. Anti-Sp1 antibody was purchased from Santa Cruz Biotechnology.
###end p 23
###begin p 24
###xml 28 36 28 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c14">14</xref>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c15">15</xref>
###xml 166 172 <span type="species:ncbi:9986">Rabbit</span>
 For immunoprecipitation of in vitro proteins the SEF and Sp1 proteins were synthesized from SEF/pCS2+MT (14) and Sp1/pCDNA (15), respectively, using the TNT Coupled Rabbit Reticulocyte Lysate system (Promega). In brief, 15 microl of SEF protein and 15 microl of Sp1 protein were mixed in 170 microl of binding buffer, incubated at 4degreesC for 2 h, supplemented with anti-SEF antibody and then absorbed onto protein G-Sepharose for 1 h at 4degreesC. The proteins were then denatured in SDS sample buffer and resolved by SDS-PAGE.
###end p 24
###begin title 25
RESULTS
###end title 25
###begin title 26
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 33 38 <span type="species:ncbi:9606">human</span>
Identification of the EIE in the human PAX6 P1 promoter
###end title 26
###begin p 27
###xml 12 14 12 14 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c13">13</xref>
###xml 99 100 99 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f1">1</xref>
###xml 117 121 117 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 365 366 365 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f1">1</xref>
###xml 561 571 561 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 561 571 <span type="species:ncbi:7227">Drosophila</span>
Previously (13) we identified a 57 bp region in exon 1 (from position +109 to position +166) (Fig. 1) that increased PAX6 promoter activity in U87 and K562 cells. Sequence analyses of E1E revealed several potential regulatory factor binding sites, including an E1E-1 site (CAGAGGTCA), an E1E-2 site (CTAATG), an E1E-3 site (CCAGTGAGGAGCGG) and four Sp1 sites (Fig. 1). The sequences of the E1E-1, E1E-2 and E1E-3 binding regions are similar to the binding sequence of the transcription factor apolipoprotein AI regulatory protein-1 (ARP-1), Islet-1 (Isl-1) and Drosophila serendipity-beta (D-Sry-beta), respectively.
###end p 27
###begin title 28
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
Characterization of the PAX6 P1 promoter enhancer E1E by EMSA
###end title 28
###begin p 29
###xml 234 236 234 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 392 393 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f2">2</xref>
###xml 470 471 470 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f2">2</xref>
###xml 597 598 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f2">2</xref>
###xml 689 693 689 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
To characterize the specificity of the DNA-protein binding affinity of each potential transcription factor binding site in E1E, double-stranded oligonucleotides corresponding to each binding site were synthesized and end-labeled with 32P for use as probes. Nuclear extracts were prepared from U251 cells. As shown by EMSA, no DNA-protein complexes formed with the E1E-1 oligonucleotide (Fig. 2, lane 1) and a weak complex was formed with the E1E-2 oligonucleotide (Fig. 2, lane 2). In contrast, a strong complex was formed with the E1E-3 oligonucleotide and nuclear extracts from U251 cells (Fig. 2, lane 4), indicating the presence of proteins binding both the E1E-2 and E1E-3 regions in PAX6 exon 1.
###end p 29
###begin p 30
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="gke490tb1">1</xref>
###xml 385 386 385 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f2">2</xref>
###xml 943 944 943 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f2">2</xref>
###xml 1050 1051 1050 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f3">3</xref>
###xml 1146 1147 1146 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f2">2</xref>
###xml 1264 1265 1264 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f2">2</xref>
###xml 1613 1616 1613 1616 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5&#8211;6</sub>
###xml 1625 1627 1625 1627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c14">14</xref>
###xml 1628 1630 1628 1630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c16">16</xref>
 To determine whether the 6 bp E1E-2 and the 14 bp E1E-3 sequences were critical for the formation of DNA-protein complexes, mutant E1E-2 and E1E-3 oligonucleotides (mE1E-2 and mE1E3, respectively) were synthesized (Table 1) and used as probes in EMSA. In contrast to the wild-type oligonucleotide, mE1E-2 did not form DNA-protein complexes with proteins in the nuclear extracts (Fig. 2, lane 3). Since the sequence of E1E-2 is similar to that of the binding site of transcription factor Isl-1, Isl-1 antibody (Santa Cruz Biotechnology) was added to the EMSA reaction to determine if the E1E-2 binding protein was Isl-1. Surprisingly, no supershift or decrease in the amount of DNA-protein complexes was demonstrated (data not shown), indicating that the protein in the E1E-2 complex was not Isl-1. Gel shift competition experiments were used to examine nuclear protein binding to E1E-3. The E1E-3 probe bound well with nuclear proteins (Fig. 2, lane 4) and excess unlabeled oligonucleotide effectively competed labeled oligonucleotide binding (Fig. 3A, lane 2). Mutation of the three central nucleotides in E1E-3 (m1E1E-3) reduced binding (Fig. 2, lane 5). Mutation of three nucleotides on either side of the E1E-3 binding site completely abolished binding (Fig. 2, lanes 6 and 7). Thus, proteins in the glioma cell nuclear extract bind to both the E1E-2 and E1E-3 regions in a sequence-specific manner and the nucleotides adjacent to the E1E-3 region appear to be more critical for binding than those in the middle. Comparison of the E1E-3 region (5'-CCAGTGAGGAGCGGT-3') with the consensus binding site 5'-CNRGN5-6CNRG-3' (14,16) showed matches at 13 of 14 positions.
###end p 30
###begin title 31
SEF binding to E1E-3
###end title 31
###begin p 32
###xml 236 240 236 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SAA3</italic>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c14">14</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c15">15</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c17">17</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c19">19</xref>
###xml 368 372 368 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 453 457 453 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SAA3</italic>
###xml 572 573 572 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f3">3</xref>
###xml 744 745 744 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f3">3</xref>
###xml 897 898 897 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f3">3</xref>
###xml 1139 1140 1139 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f3">3</xref>
###xml 1230 1231 1230 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f3">3</xref>
###xml 1423 1427 1423 1427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 1492 1500 1492 1500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1521 1522 1521 1522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f4">4</xref>
###xml 1617 1618 1617 1618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f4">4</xref>
###xml 1755 1756 1755 1756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f4">4</xref>
###xml 1832 1840 1832 1840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 2229 2230 2229 2230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f4">4</xref>
###xml 2329 2333 2329 2333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 212 217 <span type="species:ncbi:9606">human</span>
###xml 540 545 <span type="species:ncbi:9606">human</span>
###xml 1107 1113 <span type="species:ncbi:9986">rabbit</span>
Because of the high sequence similarity of the EIE-3 and SEF binding sequences, we investigated whether SEF could be the transcription factor that binds the E1E-3 site. SEF is a transcription factor encoding the human serum amyloid A3 (SAA3) gene enhancer (14,15). SEF has also been called LBP-1c/CP2/LSF (17-19). To determine whether SEF binds to the E1E-3 region in PAX6, the oligonucleotides corresponding to E1E-3 and the binding site of SEF in the SAA3 promoter were labeled and used as probes in EMSA with nuclear extracts from LN229 human cells. As shown in Figure 3A, the binding activity of E1E-3 oligonucleotide was competed by itself (lane 2) and by wild-type SEFB (lane 4), but not by the mutant forms of each oligonucleotide (Fig. 3A, lanes 3 and 5). The binding activity of SEF was competed by itself and by wild-type E1E-3, but not by the mutant forms of each oligonucleotide (Fig. 3A, lanes 8 and 10). These results indicate that SEF protein binds to the E1E-3 region. To determine if SEF binds to the E1E-3 region, supershift experiments were performed with anti-SEF antibody and preimmune rabbit serum as a control (Fig. 3B). Both SEF and E1E-3 DNA-protein complexes were supershifted by anti-SEF antibody (Fig. 3B, lanes 3-5 and 8-10). Thus, the protein complexes formed with E1E-3 and the SEF probe involved the same SEF protein. The conclusion that SEF protein binds to the E1E-3 binding region of the PAX6 P1 promoter was confirmed by EMSA using SEF protein synthesized in vitro. As shown in Figure 4, both EIE-3 and SEF oligonucleotides bind to SEF protein and form protein-DNA complexes (Fig. 4, lanes 1 and 11). The binding activities of both EIE-3 and the SEF probe are competed by themselves but not by their mutant forms (Fig. 4, lanes 2-6 and 7-10). In order to confirm that the SEF protein synthesized in vitro was the oligonucleotide binding component, SEF protein was mixed with SEF antibody before addition of labeled EIE-3 or SEF oligonucleotide and complex formation was assayed by EMSA. In the absence of SEF antibody appropriate complexes were formed. Increasing amounts of SEF antibody reduced the amount of SEF protein driven into protein-DNA complexes with the oligonucleotide probe (Fig. 4, lanes 13-16 and 18-20). These results indicate that SEF protein binds to the EIE-3 region of the PAX6 promoter.
###end p 32
###begin title 33
Functional analysis of the putative transcription factor binding sites in E1E
###end title 33
###begin p 34
###xml 94 98 94 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 155 156 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f1">1</xref>
###xml 293 294 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="gke490tb2">2</xref>
###xml 381 382 381 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="gke490tb1">1</xref>
###xml 752 753 752 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f5">5</xref>
The function of the three putative transcription factor binding sites in the exon 1 region of PAX6 (E1E-1, E1E-2 and E1E-3) and the Sp1 binding site (Fig. 1) were examined. Constructs with mutations in the binding sites were generated by PCR-based site-directed mutagenesis of 346pGL3B (Table 2). The mutations were the same as those in the mutated oligonucleotides shown in Table 1. The luciferase constructs were examined for promoter activity by transient transfection into U251 and LN229 cells. For comparison, the cells were also transfected with the luciferase construct without the promoter and enhancer (pGL3B). The structures of the mutant constructs and their promoter activities determined by transient expression assays are shown in Figure 5. For comparison, the luciferase activities were normalized to the activity of 346pGL3B.
###end p 34
###begin p 35
###xml 99 100 99 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f2">2</xref>
###xml 318 319 318 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f1">1</xref>
###xml 498 502 498 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 63 68 <span type="species:ncbi:9606">human</span>
 Although the E1E-1 region did not bind to nuclear extracts of human glioblastoma cell lines (Fig. 2), mutations in this region resulted in a 70-90% reduction in transactivation. However, a search of the database of transcription factor binding sites indicated that an Sp1 binding site overlaps the E1E-1 region (Fig. 1). Thus, this decrease in promoter activity may have been caused by a mutation in the Sp1 site rather than in E1E-1, and it is possible that this Sp1 binding site is important in PAX6 promoter function.
###end p 35
###begin p 36
###xml 86 87 86 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f2">2</xref>
###xml 190 194 190 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 475 479 475 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 537 541 537 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
 Mutation in the E1E-2 region (the same mutation that abolished binding shown in Fig. 2) did not substantially affect promoter activity, suggesting that the E1E-2 region is not necessary in PAX6 P1 promoter function. Two mutations in E1E-3 abolished binding activity and resulted in a 70-90% reduction in promoter activity. Deletion of the Sp1 binding region in E1E led to an 80-95% reduction in promoter activity. Together, these data suggest that the E1E-3 binding site in PAX6 and the adjacent Sp1 binding site are both important for PAX6 P1 promoter activity.
###end p 36
###begin title 37
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
In vitro interaction between SEF and Sp1
###end title 37
###begin p 38
###xml 304 308 304 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 614 615 614 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f6">6</xref>
###xml 705 713 705 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 744 745 744 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f6">6</xref>
###xml 851 852 851 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f6">6</xref>
###xml 952 960 952 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1000 1001 1000 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f6">6</xref>
###xml 1115 1116 1115 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f6">6</xref>
###xml 1190 1198 1190 1198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
Sp1 is a ubiquitous transcription factor whose binding site, a GC box, is widely distributed in promoter regions of many genes. Because the SEF binding site (E1E-3) in E1E is adjacent to Sp1 binding sites, we hypothesized that the two transcription factors SEF and Sp1 may cooperate in the regulation of PAX6 gene expression. LN229 nuclear extracts and SEF and Sp1 protein mixtures were immunoprecipitated with polyclonal anti-SEF antibody in separate experiments. Then the proteins in immunocomplexes were detected with anti-Sp1 antibody. As a positive control, immunoprecipitation by Sp1 antibody was done (Fig. 6, lanes 3, 9 and 11). Negative controls showed that the Sp1 antibody was unable to detect in vitro synthesized SEF protein (Fig. 6, lanes 7 and 12) and ruled out a cross-reaction between Sp1 antibody and SEF protein. As shown in Figure 6, Sp1 protein was detected in the SEF immunocomplexes from nuclear extracts and from the mixture of in vitro synthesized SEF and Sp1 proteins (Fig. 6, lanes 2 and 6). In contrast, an unrelated antibody (anti-PAX6 antibody) failed to precipitate Sp1 protein (Fig. 6, lane 4). These results indicate that SEF can interact directly with Sp1 in vitro.
###end p 38
###begin title 39
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
Involvement of SEF and Sp1 in PAX6 regulation
###end title 39
###begin p 40
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 137 141 137 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 798 799 795 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f7">7</xref>
###xml 895 896 892 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f7">7</xref>
###xml 945 949 942 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 992 993 989 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f7">7</xref>
###xml 1060 1061 1057 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gke490f7">7</xref>
###xml 1207 1211 1204 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 131 136 <span type="species:ncbi:9606">human</span>
###xml 308 312 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
To determine whether SEF and Sp1 were involved in the regulation of PAX6 gene expression, LN229 cells were co-transfected with the human PAX6 promoter-luciferase construct 346pGL3B, an Sp1 expression construct, Sp1/pCDNA3.1, or an SEF expression construct, SEF/pCS2+MT. Because SEF can bind and activate the SV40 major late promoter, the beta-galactosidase-expressing vector pSV40-pSV2 cannot be used as an internal control in these transfection experiments. Instead, luciferase activity was normalized to the amount of protein in the cell lysate. The same amounts of 346pGL3B were used in each transfection experiment and different amounts of vector pCS2+MT were used to maintain the same total amount of DNA. The amount of SEF expression construct SEF/pCS2+MT was increased from 0 to 10 ng (Fig. 7A) and the amount of Sp1 expression construct SP1/pCDNA3.1 was increased from 0 to 150 ng (Fig. 7B). These results showed that SEF could increase PAX6 gene promoter activity up to 4-fold (Fig. 7A) and Sp1 could increase the promoter activity up to 6-fold (Fig. 7B). Although there seems to be a physical interaction between SEF and SP1 this interaction alone does not result in synergistic activation of the PAX6 promoter. It seems likely that other factors are necessary for high level transactivation.
###end p 40
###begin title 41
DISCUSSION
###end title 41
###begin p 42
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 469 470 469 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c1">1</xref>
###xml 471 472 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c2">2</xref>
###xml 475 478 475 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 563 564 563 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c1">1</xref>
###xml 565 566 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c3">3</xref>
###xml 696 700 696 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 713 716 713 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 754 755 754 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c1">1</xref>
###xml 756 757 756 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c4">4</xref>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c13">13</xref>
###xml 67 72 <span type="species:ncbi:10090">mouse</span>
###xml 96 101 <span type="species:ncbi:9606">human</span>
Transcriptional regulatory regions of PAX6 have been identified in mouse, quail, pufferfish and human. These regions are generally very highly conserved. The two upstream promoters P0 and P1 are remarkable in both their nucleotide sequence arrangement and spatio-temporal expression during evolution. The P0 promoter is activated at the onset of neuronal differentiation and P0 transcripts are found in the lens placode, corneal and conjuntival epithelia and pancreas (1,2). cis-regulatory elements for P0 have been found within 6 kb upstream of the P0 promoter (1-3). The P1 promoter control region is less well characterized. P1-initiated transcripts are found in all eye structures expressing PAX6 and several cis-acting elements have been described (1-4,13), but no specific transcriptional activators have been identified.
###end p 42
###begin p 43
###xml 18 20 18 20 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c13">13</xref>
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 148 152 148 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 278 281 278 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 330 334 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 472 476 472 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c13">13</xref>
###xml 779 783 779 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 795 798 795 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 866 870 866 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 973 977 973 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 1116 1120 1116 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 62 67 <span type="species:ncbi:9606">human</span>
###xml 773 778 <span type="species:ncbi:9606">human</span>
 Xu and Saunders (13) previously cloned and characterized the human PAX6 P1 promoter and identified the transcription initiation site and the 92 bp PAX6 minimal promoter (bp-62 to +30). They found by deletion analysis of the 346 bp fragment (-180 to +166, pCSMNA) that multiple cis elements located upstream and downstream of the PAX6 transcription initiation site are responsible for high level basal promoter activity and cell specificity. Using deletion mutants of the PAX6 P1 promoter, Xu and Saunders (13) performed transient transfection experiments in different cell lines and predicted that there may be a 57 bp enhancer in the P1 promoter region. In this paper we have identified and characterized this 57 bp region (E1E), which is important for expression of the human PAX6 gene. This cis-regulatory element is located in the 5'-untranslated region of the PAX6 gene, 109 bp downstream of the transcription start site and 370 bp before the start of translation in PAX6 mRNA. We have determined that the transcription factors SEF and Sp1 are essential transcription factors for E1E and that they up-regulate PAX6 transcription.
###end p 43
###begin p 44
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 149 153 149 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 196 200 196 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
 By mutation of the putative TATA box in the PAX6 P1 promoter and transient transfection experiments, we confirmed that the putative TATA box in the PAX6 P1 minimal promoter is functional for the PAX6 P1 promoter (data not shown).
###end p 44
###begin p 45
###xml 10 17 10 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> et al.</italic>
###xml 19 21 19 21 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c20">20</xref>
###xml 121 125 121 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 312 313 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c8">8</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c21">21</xref>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c23">23</xref>
###xml 441 447 441 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> et al</italic>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c20">20</xref>
###xml 568 572 568 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 729 737 729 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 872 876 872 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
 Okladnova et al. (20) identified an Isl-1 binding motif within the promoter P1. This was of particular interest because PAX6 is a key regulator for normal pancreatic islet cell development and because Isl-1 is a LIM homeodomain transcription factor that is required for motor neuron and islet cell development (8,21-23). However, our supershift experiments showed no binding of E1E-2 (the putative Isl-1 binding motif indicated by Okladnova et al.; 20) to anti-Isl-1 antibody and our transfection experiments showed that mutation of the E1E-2 region had no effect on PAX6 promoter activity. These data indicate that Isl-1 was not the factor bound to E1E-2. Although we found weak sequence-specific binding to the E1E-2 sequence in vitro, our transient transfection data strongly implied that the protein(s) that bound to this region was not involved in the regulation of PAX6 gene expression.
###end p 45
###begin p 46
###xml 109 113 109 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 372 380 372 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
 In EMSA no E1E-1 DNA-protein complexes were formed. However, mutation of this region dramatically decreased PAX6 P1 promoter activity. One possible explanation is that, because there is also a Sp1 binding site overlapping the E1E-1 region, the mutation in the E1E-1 region may affect the Sp1 site, thus affecting transcription regulation by Sp1. Alternatively, under our in vitro conditions we were unable to detect the transcription factor binding E1E-1.
###end p 46
###begin p 47
###xml 10 18 10 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 23 30 23 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 82 86 82 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 247 257 244 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 316 318 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gke490c24">24</xref>
###xml 457 460 454 457 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5&#8211;6</sub>
###xml 551 555 548 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 644 652 641 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 928 932 925 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 949 956 946 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 994 998 991 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 1093 1097 1090 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 247 257 <span type="species:ncbi:7227">Drosophila</span>
###xml 337 342 <span type="species:ncbi:9606">human</span>
 Both our in vitro and in vivo results show that the E1E-3 region is critical for PAX6 gene expression. When we searched the TESS transcription factor database () the sequence of E1E-3 matched the sequence of the zinc finger protein D-Sry-beta in Drosophila, which is involved in the onset of zygotic transcription (24) but has no known human homolog. However, part of the E1E-3 region (5'-CCAGTGAGGAGCGG) matched the consensus binding site of SEF (5'-CNRGN5-6CNRGN). As our EMSA and transient transfection experiments showed, SEF is an activator for PAX6 transcription activation. Also, we have demonstrated an interaction between SEF and Sp1 in vitro. As our data show, the activity drops with increasing amounts of overexpressed Sp1 or SEF. Since co-transfection of SEF and Sp1 activates transcription slightly more than additively (data not shown), it is possible that additional factors besides SEF and Sp1 are involved in PAX6 gene expression in vivo. Studies of how SEF and Sp1 regulate PAX6 gene expression will provide a better understanding of the temporal and spatial regulation of PAX6 gene expression.
###end p 47
###begin title 48
Figures and Tables
###end title 48
###begin p 49
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 135 138 135 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 218 221 218 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 319 324 319 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 47 52 <span type="species:ncbi:9606">human</span>
 Nucleotide sequence of the P1 promoter of the human PAX6 gene. The transcriptional start site (+1) is marked with the bent arrow. The cis element E1E is indicated in bold. The TATA-like box, CCAAT boxes and potential cis-regulatory elements in the proximal promoter region mapped by Xu and Saunders (13) and Okladnova et al. (20) are either in boxes or underlined and labeled. Essential restriction sites used in subsequent subcloning are underlined and labeled above the sequence. Intron 1 is in lower case and labeled. The exon 2 region is labeled.
###end p 49
###begin p 50
###xml 49 51 49 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="gke490tb2">2</xref>
 EMSA of potential protein binding sites in E1E. 32P-labeled probes for E1E-1, E1E-2, mE1E2, E1E-3, m1E1E3, m2E1E3 and m3E1E3 (Table 2) sites were incubated with equal amounts of protein in nuclear extracts from U251 cells.
###end p 50
###begin p 51
###xml 43 44 43 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 123 127 123 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 211 213 211 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 391 392 391 392 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
 DNA binding specificity of SEF to E1E-3. (A) EMSA with nuclear extracts. Double-stranded oligonucleotides of E1E-3 in the PAX6 P1 promoter and the SEF binding site (SEF) from the serum amyloid A3 promoter were 32P-labeled and incubated with nuclear extracts from LN229 cells. DNA-protein complexes were competed with wild-type or mutant E1E-3 or SEF oligonucleotides (lanes 2-5 and 7-10). (B) The reaction was incubated with preimmune or anti-SEF antibodies to supershift the DNA-protein complex (lanes 1-5 and 6-10) and the amounts of anti-SEF antibodies were increased to supershift the DNA-protein complex.
###end p 51
###begin p 52
###xml 95 97 95 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
 DNA binding properties of SEF protein to E1E-3. In an experiment similar to that in Figure 3, 32P-labeled E1E-3 or SEF oligonucleotides were incubated with SEF protein. The competitors used were the wild-type or mutant oligonucleotides, E1E-3 or SEF (lanes 2-5 and 7-10) or preimmune serum or anti-SEF antibodies to abolish the DNA-protein complex (lanes 12-15 and 17-20). In lanes 13-15 and 18-20 the amounts of anti-SEF antibodies were increased to abolish the DNA-protein complex.
###end p 52
###begin p 53
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 129 132 129 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sma</italic>
###xml 134 137 134 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nae</italic>
###xml 159 163 159 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 153 158 <span type="species:ncbi:9606">human</span>
 Luciferase activity of the PAX6 P1 promoter with various mutations. The 346pGL3B construct was prepared by inserting the 346 bp SmaI-NaeI region of the human PAX6 P1 promoter into a luciferase basic vector (pGL3B). Each binding site was mutated (as described in Materials and Methods). U251 and LN229 cells were transfected with 0.5 microg of the constructs shown. The results were normalized to the activity of the control pGL3 basic transfected cells, to which a value of 100 was assigned.
###end p 53
###begin p 54
###xml 69 70 69 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 222 230 222 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 310 312 310 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> 5</italic>
###xml 330 338 330 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 424 425 424 425 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 427 435 427 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
 Co-immunoprecipitation analysis of the association of SEF and Sp1. (A) Nuclear extract from LN229 cells was subjected to immunoprecipitation with anti-SEF antibody, anti-Sp1 antibody or anti-PAX6 antibody (as a control). In vitro synthesized Sp1 protein was used to indicate the position of the Sp1 band (lane 5) and a sample of in vitro synthesized SEF protein was used as a negative control for immunoblotting (lane 1). (B) In vitro synthesized SEF and Sp1 were immunoprecipitated together with anti-SEF antibody or anti-Sp1 antibody (lanes 6 and 9) or immuniprecipitated separately with anti-SEF antibody or anti-Sp1 antibody (lanes 7, 8, 10 and 11). Anti-Sp1 antibody was used to probe the membrane.
###end p 54
###begin p 55
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAX6</italic>
###xml 77 78 77 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 351 352 351 352 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
 Transactivation of the PAX6 promoter by SEF and Sp1 expression constructs. (A) LN229 cells were co-transfected with 50 ng of 346pGL3B and increasing amounts of SEF expression plasmid DNA. The luciferase activities were normalized to the activity of 346pGL3B with co-transfection of the empty vector, to which a value of 1.0 was assigned (column 1). (B) LN229 cells were co-transfected with 50 ng of 346pGL3B and increasing amounts of the Sp1 expression plasmid DNA. The data were calculated from nine independent experiments repeated three or four times.
###end p 55
###begin title 56
 Oligonucleotides used for EMSA for mutant E1E binding sites
###end title 56
###begin p 57
The binding site is in bold, the mutant position is italic.
###end p 57
###begin title 58
###xml 0 60 0 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Oligonucleotides used in PCR-based site-directed mutagenesis</italic>
Oligonucleotides used in PCR-based site-directed mutagenesis
###end title 58
###begin p 59
Mutant sites are in bold.
###end p 59
###begin title 60
ACKNOWLEDGEMENTS
###end title 60
###begin p 61
We are thankful to Ruby S. Desiderio and Rama Grenda for preparation of this manuscript. We are also grateful to the late Dr Peter A. Steck for providing the U251and LN229 cell lines. This work was supported by NRSA grant 5 F32 EY06949-02 and NIH grants EY09675 and EY10608.
###end p 61

